Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 12
Submit an article Journal homepage
92
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluations

Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer

Scott S Tykodi University of Washington, Division of Medical Oncology, Department of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4-830, Seattle, WA 98109-1023, USA +1 206 288 2044; +1 206 288 6210; [email protected]
, MD PhD &
John A Thompson University of Washington, Division of Medical Oncology, Department of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4-830, Seattle, WA 98109-1023, USA +1 206 288 2044; +1 206 288 6210; [email protected]
, MD
Pages 1947-1953 | Published online: 06 Nov 2008

Bibliography

  • Papac RJ. Spontaneous regression of cancer. Cancer Treat Rev 1996;22:395-423
  • Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4
  • Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303
  • Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
  • Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988;57:239-46
  • Myers KA, Rahi-Saund V, Davison MD, et al. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem 1994;269:9319-24
  • Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-95
  • Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005;93:670-7
  • Ali A, Langdon J, Stern P, Partridge M. The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa. Oral Oncol 2001;37:57-64
  • Imamura F, Nagao H, Naritsuka H, et al. A leucine-rich repeat membrane protein, 5T4, is expressed by a subtype of granule cells with dendritic arbors in specific strata of the mouse olfactory bulb. J Comp Neurol 2006;495:754-68
  • Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84-92
  • Jones H, Roberts G, Hole N, et al. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer 1990;61:96-100
  • Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992;66:867-9
  • Naganuma H, Kono K, Mori Y, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002;22:1033-8
  • Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899-902
  • Wrigley E, McGown AT, Rennison J, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995;5:269-74
  • Mulder WM, Stern PL, Stukart MJ, et al. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 1997;3:1923-30
  • Starzynska T, Wiechowska-Kozlowska A, Marlicz K, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol 1998;10:479-84
  • Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003;3:263-71
  • Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55:1081-90
  • Mulryan K, Ryan MG, Myers KA, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002;1:1129-37
  • Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin Cancer Res 2006;12:3416-24
  • Dangoor A, Burt D, Harrop R, et al. A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial [abstract #2574]. J Clin Oncol 2006;24:(18 Suppl)
  • Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487-94
  • Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008;57:977-86
  • Cao A, Hernandez-McClain J, Willis JP, et al. Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-a (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC) [abstract #3069]. J Clin Oncol 2007;25:(18 Suppl)
  • Harrop R, Macdermott C, Shablak A, et al. Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFNa: A Phase II trial [abstract #3053]. J Clin Oncol 2008;26:(15 Suppl)
  • Hernandez-McClain J, Amato RJ, Shingler WH, et al. Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax[T]) administered + low dose interleukin-2 (IL-2): A Phase II trial [abstract #5101]. J Clin Oncol 2008;26:(15 Suppl)
  • Kaufman HL, Kim-Schulze S, Kim D, et al. Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2 [abstract #3004]. J Clin Oncol 2008;26:(15 Suppl)
  • TroVax Renal Immunotherapy Survival Trial. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00397345 [Last Accessed 3 October 2008]
  • Oxford BioMedica Announces Data Safety Monitoring Board Recommendation For TroVax® Phase III TRIST Study. Available from: http://www.oxfordbiomedica.co.uk/news/2008-ob-21.asp [Last Accessed 3 October 2008]
  • Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008;31:577-85
  • Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00521274 [Last Accessed 7 October 2008]
  • Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
  • Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12:3064-9
  • Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
  • Letter to Investigators - 15 July 2008. Available from: http://www.trovax.co.uk/pdfs/investigators.pdf [Last Accessed October 6, 2008]
  • Products / TroVax®. Available from: http://www.oxfordbiomedica.co.uk/Trovax.asp [Last Accessed October 6, 2008]
  • Redchenko I, Harrop R, Ryan MG, et al. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 2006;118:50-7
  • Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008;20:1057-66
  • Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53
  • Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.